Vulval/vaginal cancer

Jessica Lee, John P. Curtin

Research output: Chapter in Book/Report/Conference proceedingChapter


Vulvar/vaginal cancer is the fourth most common gynecologic cancer accounting for 5% of female genital tract malignancies. The signs and symptoms of vulvar cancer are similar despite different histologic subtypes. Primary vaginal cancer comprises approximately 3% of gynecologic malignancies. Most patients present with vaginal bleeding or discharge but many are asymptomatic. As with vulvar cancer, a biopsy of any suspicious vaginal lesion either in the outpatient setting or in the operating room can diagnose the malignancy. This chapter explores how immunosuppression contribute to the development of preinvasive or invasive cancer in women. It focuses on whether concurrent chemotherapy with radiation therapy compared to primary surgery improve clinical response in patients with unresectable locally advanced vulvar cancer. For vaginal cancer, primary surgery is rarely performed due to the close proximity of vaginal tumors to critical organs and the high risk of significant complications.

Original languageEnglish (US)
Title of host publicationEvidence-based Obstetrics and Gynecology
Number of pages8
ISBN (Electronic)9781119072980
StatePublished - 2018


  • Chemotherapy
  • Female genital tract malignancies
  • Gynecologic cancer
  • Immunosuppression
  • Lesion Vulvar/vaginal cancer
  • Radiation therapy
  • Vaginal
  • Vaginal bleeding
  • Vaginal discharge

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Vulval/vaginal cancer'. Together they form a unique fingerprint.

Cite this